• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利培酮衍生物与D2多巴胺受体的分子对接研究

Molecular Docking studies of D2 Dopamine receptor with Risperidone derivatives.

作者信息

Bhargava Kiran, Nath Rajendra, Seth Prahlad Kumar, Pant Kamlesh Kumar, Dixit Rakesh Kumar

机构信息

Department of Pharmacology and Therapeutics, King George's Medical University Erstwhile CSMMU, Lucknow 226003, UP,India.

Biotech Park, Lucknow-226021, UP, India.

出版信息

Bioinformation. 2014 Jan 29;10(1):8-12. doi: 10.6026/97320630010008. eCollection 2014.

DOI:10.6026/97320630010008
PMID:24516319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3916812/
Abstract

In this work, 3D model of D2 dopamine receptor was determined by comparative homology modeling program MODELLER. The computed model's energy was minimized and validated using PROCHECK and Errat tool to obtain a stable model structure and was submitted in Protein Model Database (PMDB-ID: PM0079251). Stable model was used for molecular docking against Risperidone and their 15 derivatives using AutoDock 4.2, which resulted in energy-based descriptors such as Binding Energy, Ligand Efficiency, Inhib Constant, Intermol energy, vdW + Hbond + desolv Energy, Electrostatic Energy, Total Internal Energy and Torsional Energy. After that, we have built quantitative structure activity relationship (QSAR) model, which was trained and tested on Risperidone and their 15 derivatives having activity value pKi in µM. For QSAR modeling, Multiple Linear Regression model was engendered using energy-based descriptors yielding correlation coefficient r2 of 0.513. To assess the predictive performance of QSAR models, different cross-validation procedures were adopted. Our results suggests that ligand-receptor binding interactions for D2 employing QSAR modeling seems to be a promising approach for prediction of pKi value of novel antagonists against D2 receptor.

摘要

在本研究中,通过比较同源性建模程序MODELLER确定了D2多巴胺受体的三维模型。使用PROCHECK和Errat工具对计算得到的模型能量进行最小化和验证,以获得稳定的模型结构,并将其提交至蛋白质模型数据库(PMDB-ID:PM0079251)。使用AutoDock 4.2将稳定的模型用于与利培酮及其15种衍生物进行分子对接,从而得到基于能量的描述符,如结合能、配体效率、抑制常数、分子间能量、范德华力+氢键+去溶剂化能量、静电能、总内能和扭转能。之后,我们构建了定量构效关系(QSAR)模型,该模型在利培酮及其15种活性值以微摩尔为单位的pKi衍生物上进行训练和测试。对于QSAR建模,使用基于能量的描述符生成了多元线性回归模型,相关系数r2为0.513。为了评估QSAR模型的预测性能,采用了不同的交叉验证程序。我们的结果表明,采用QSAR建模研究D2的配体-受体结合相互作用似乎是预测新型D2受体拮抗剂pKi值的一种有前景的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/fc757f96fc0d/97320630010008F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/47969ff03c49/97320630010008F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/0bb049ef2ffc/97320630010008F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/8ee19b18ca08/97320630010008F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/fc757f96fc0d/97320630010008F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/47969ff03c49/97320630010008F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/0bb049ef2ffc/97320630010008F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/8ee19b18ca08/97320630010008F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7161/3916812/fc757f96fc0d/97320630010008F4.jpg

相似文献

1
Molecular Docking studies of D2 Dopamine receptor with Risperidone derivatives.利培酮衍生物与D2多巴胺受体的分子对接研究
Bioinformation. 2014 Jan 29;10(1):8-12. doi: 10.6026/97320630010008. eCollection 2014.
2
Identification of Ellagic acid analogues as potent inhibitor of protein Kinase CK2:A chemopreventive role in oral Cancer.鉴定鞣花酸类似物作为蛋白激酶CK2的有效抑制剂:在口腔癌中的化学预防作用。
Bioinformation. 2015 Jan 30;11(1):21-6. doi: 10.6026/97320630011021. eCollection 2015.
3
QSAR modeling and docking analysis of D2 receptor with known olanzapine derivatives.D2受体与已知奥氮平衍生物的定量构效关系建模及对接分析
Bioinformation. 2020 Sep 30;16(9):666-671. doi: 10.6026/97320630016666. eCollection 2020.
4
A QSAR model of Olanzapine derivatives as potential inhibitors for 5-HT2A Receptor.奥氮平衍生物作为5-HT2A受体潜在抑制剂的定量构效关系模型。
Bioinformation. 2017 Oct 31;13(10):339-342. doi: 10.6026/97320630013339. eCollection 2017.
5
The Universal 3D QSAR Model for Dopamine D Receptor Antagonists.多巴胺 D 受体拮抗剂的通用 3D QSAR 模型。
Int J Mol Sci. 2019 Sep 14;20(18):4555. doi: 10.3390/ijms20184555.
6
KiDoQ: using docking based energy scores to develop ligand based model for predicting antibacterials.KiDoQ:利用基于对接的能量评分开发基于配体的模型,用于预测抗菌药物。
BMC Bioinformatics. 2010 Mar 11;11:125. doi: 10.1186/1471-2105-11-125.
7
Design of novel dopamine D and serotonin 5-HT receptors dual antagonists toward schizophrenia: An integrated study with QSAR, molecular docking, virtual screening and molecular dynamics simulations.新型多巴胺 D 和血清素 5-HT 受体双重拮抗剂设计用于治疗精神分裂症:基于 QSAR、分子对接、虚拟筛选和分子动力学模拟的综合研究。
J Biomol Struct Dyn. 2020 Feb;38(3):860-885. doi: 10.1080/07391102.2019.1590244. Epub 2019 Mar 27.
8
A ClpP protein model as tuberculosis target for screening marine compounds.一种作为结核病靶点用于筛选海洋化合物的ClpP蛋白模型。
Bioinformation. 2010 Mar 31;4(9):405-8. doi: 10.6026/97320630004405.
9
A QSAR model of benzoxazole derivatives as potential inhibitors for inosine 5`-monophosphate dehydrogenase from Cryptosporidium parvum.作为微小隐孢子虫肌苷5'-单磷酸脱氢酶潜在抑制剂的苯并恶唑衍生物的定量构效关系模型。
Bioinformation. 2016 Jun 15;12(3):119-123. doi: 10.6026/97320630012119. eCollection 2016.
10
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.基于比较分子力场分析(CoMFA)对重组D1和D2多巴胺受体激动剂亲和力的预测
J Med Chem. 1998 Oct 22;41(22):4385-99. doi: 10.1021/jm9800292.

引用本文的文献

1
QSAR modeling and docking analysis of D2 receptor with known olanzapine derivatives.D2受体与已知奥氮平衍生物的定量构效关系建模及对接分析
Bioinformation. 2020 Sep 30;16(9):666-671. doi: 10.6026/97320630016666. eCollection 2020.
2
Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis.多巴胺调节剂的重新定位及其在精神分裂症中的潜在应用:药效团映射、分子对接和分子动力学分析。
ACS Omega. 2021 Jun 1;6(23):14748-14764. doi: 10.1021/acsomega.0c05984. eCollection 2021 Jun 15.

本文引用的文献

1
Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia.非典型抗精神病药物改善精神分裂症认知功能的神经基础。
Front Behav Neurosci. 2013 Oct 16;7:140. doi: 10.3389/fnbeh.2013.00140.
2
Antipsychotic treatments; focus on lurasidone.抗精神病药物治疗;专注于鲁拉西酮。
Front Pharmacol. 2013 Aug 26;4:102. doi: 10.3389/fphar.2013.00102. eCollection 2013.
3
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.老年人使用利培酮和第一代抗精神病药物的运动障碍:一项加拿大基于人群的研究。
PLoS One. 2013 May 16;8(5):e64217. doi: 10.1371/journal.pone.0064217. Print 2013.
4
[Drug induced movement disorders: role of antipsychotic drugs].
Acta Med Port. 2011 Dec;24 Suppl 4:915-22. Epub 2011 Dec 31.
5
Typical and atypical neuroleptics.
Handb Clin Neurol. 2011;100:579-99. doi: 10.1016/B978-0-444-52014-2.00042-2.
6
The physiology, signaling, and pharmacology of dopamine receptors.多巴胺受体的生理学、信号转导和药理学。
Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8.
7
Cranial Nerves IX, X, XI, and XII.第九、十、十一和十二对脑神经。
Psychiatry (Edgmont). 2010 May;7(5):37-41.
8
KiDoQ: using docking based energy scores to develop ligand based model for predicting antibacterials.KiDoQ:利用基于对接的能量评分开发基于配体的模型,用于预测抗菌药物。
BMC Bioinformatics. 2010 Mar 11;11:125. doi: 10.1186/1471-2105-11-125.
9
Recent advances in treating cognitive impairment in schizophrenia.精神分裂症认知障碍治疗的最新进展
Psychopharmacology (Berl). 2009 Jan;202(1-3):259-73. doi: 10.1007/s00213-008-1302-9. Epub 2008 Sep 3.
10
Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia.利培酮治疗儿童和青少年双相情感障碍及精神分裂症的评价。
Neuropsychiatr Dis Treat. 2008 Feb;4(1):55-68.